The global Edward’s syndrome treatment market is expected to garner a market value of US$ 4.9 Billion in 2023 and is expected to accumulate a market value of US$ 7.98 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The growth of Edward’s syndrome treatment market can be attributed to an increase in investment in research and development. The market for Edward’s syndrome registered a CAGR of 3% in the historical period 2018 to 2022
Edwards syndrome, also known as Trisomy 18, is a chromosomal disorder that occurs in about 1 in 5,000 live births. The condition is characterized by severe intellectual disability and physical abnormalities, and many affected infants do not survive beyond the first few months of life.
It is possible that with the advancement of medical technology, doctors are now able to diagnose Edwards syndrome more accurately and earlier in pregnancy, which may lead to an increase in demand for treatment. Additionally, with the increasing popularity of genetic testing, more families may be learning about the diagnosis in their family, leading to more demand for treatment.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.9 Billion |
| Anticipated Forecast Value (2033) | US$ 7.98 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Edward’s syndrome treatment reflected a value of 3% during the historical period, 2018 to 2022.
Treatment for Edwards syndrome focuses mainly on addressing the symptoms and complications that result from the condition. There is no cure for Edwards syndrome, and treatment is supportive in nature. It usually involves a team of healthcare professionals such as physicians, nurses, genetic counselors, occupational therapists, physical therapists, speech therapists, and social workers to provide comprehensive care. The focus is on providing medical care and support to the affected individual and their families in order to improve their quality of life. Treatments may include surgery, physiotherapy, speech therapy, and support for developmental milestones.
Thus, the market for Edward’s syndrome treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Improved healthcare infrastructure and government initiatives supporting market growth
The rapid rise in cases of central nervous system disorder is expected to accelerate the market growth in the forecast period of 2023 to 2033. Likewise, the increase in the occurrence of Edwards syndrome and rise in the healthcare spending is also predictable to enhance the Edwards syndrome treatment market growth. Furthermore, the increased government support and the rise in genetic counseling are also projected to drive the market growth rate.
In addition, the technological advancements for effective treatment and the easy availability of advanced healthcare facilities are likely to create various new opportunities that will impact this Edwards syndrome market growth in the forecast period of 2023 to 2033.
The availability of various treatments creates lucrative opportunities for the Edwards syndrome market
Treatment for Edwards syndrome primarily focuses on managing the symptoms and complications that arise from the condition.
Prenatal care: when a fetus is diagnosed with Edwards syndrome, regular prenatal care can help monitor the baby's growth and development, as well as prepare for the delivery and care of the baby after birth.
Medical management: infants with Edwards syndrome often have a range of medical issues that need to be addressed, such as heart defects, respiratory problems, and feeding difficulties. Treatment may involve surgery, medication, and other therapies to address these issues.
Supportive care: infants with Edwards syndrome will require extensive care and support to address their physical and intellectual disabilities. This may include physical therapy, occupational therapy, speech therapy, and other forms of rehabilitation to help them reach their full potential.
Genetic counseling: for families who have a child with Edwards syndrome, genetic counseling may be recommended to help them understand the condition and the risks of recurrence in future
Principal Consultant
Lack of awareness and failure of treatment hindering the overall market growth
The high treatment cost and lack of awareness about the treatment are expected to act as major restraints towards the growth of the Edwards syndrome market, whereas lack of awareness amongst patients can challenge the growth of the target market in the above-mentioned forecast period.
Certain treatments may improve some of the symptoms, but they do not cure the underlying genetic problem. Even with the best care, most infants with Edwards syndrome do not survive past their first year of life. Thus, all these factors are hampering the growth of the overall market.
Government-based foundations help families to understand Edwards syndrome better
In North America prenatal screening is offered to all pregnant women as part of their routine care. The screening allows for the identification of fetuses at increased risk of chromosomal disorders such as Edward syndrome, where then follow-up diagnostic tests, such as chorionic villus sampling or amniocentesis, can confirm or exclude the diagnosis. With the advancement of prenatal screening and diagnostic technologies, doctors are now able to diagnose Edwards syndrome more accurately and earlier in pregnancy which could lead to an increase in demand for treatment.
It's worth mentioning that, in North America, there are also a number of organizations that provide support and resources for families affected by Edwards syndrome, such as the Trisomy 18 Foundation. These organizations can help families connect with others who have experience with the condition, learn about treatments and resources, and advocate for their loved one's care.
Thus, North America is expected to possess a 45% market share of the Edwards syndrome treatment market in 2023.
Integration of technology offering better results for diagnostic tests
Healthcare systems and resources vary greatly across the countries and regions of Asia Pacific, especially in China, India, and Japan. This, in turn, has created wide availability and accessibility of treatments for Edwards syndrome in the region. With increasing access to better healthcare resources and genetic screening techniques, the diagnostics and treatments for Edwards Syndrome are expected to improve in the region.
Furthermore, the presence of well-developed healthcare infrastructure and favorable government support. Thus, Asia Pacific is expected to hold a 39% market share for Edwards syndrome treatment in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end-user, the Edwards syndrome treatment market is segmented into Hospitals, Clinics, Ambulatory Surgical Centres, Others
The hospital segment is expected to hold the largest market share for Edward’s syndrome treatment. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of Edward’s syndrome treatment.
Furthermore, initiatives by government authorities to support the treatment of Edward’s syndrome treatment, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Edward’s syndrome treatment. Thus, hospitals are expected to hold a 40% market share of Edward’s syndrome treatment market in 2023.
Key players in the Edwards syndrome treatment market are Merck & Co, Kyorin Pharmaceuticals, Pfizer Inc, Bellus Health, Eli Lilly and Company, GeneScience Pharmaceuticals Co., Ltd, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sanofi, Bayer AG
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.9 Billion |
| Market Value in 2033 | US$ 7.98 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The Edward’s syndrome treatment market is expected to garner a market value of US$ 4.9 Billion in 2023.
India, Japan, and China dominate the Asian market.
Improved healthcare infrastructure and the availability of various treatments drive market growth.
The hospital segment is expected to lead the market.
The high treatment cost and lack of awareness about the treatment limits the growth potential.
1. Executive Summary | Edward’s Syndrome Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018-2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018-2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Types 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Types, 2018-2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Types, 2023 to 2033 5.3.1. Full Trisomy 18 5.3.2. Mosaic Trisomy 18 5.3.3. Partial Trisomy 18 5.4. Y-o-Y Growth Trend Analysis By Types, 2018-2022 5.5. Absolute $ Opportunity Analysis By Types, 2023 to 2033 6. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018-2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. Cardiac Treatment 6.3.2. Assisted Feeding 6.3.3. Orthopaedic Treatment 6.3.4. Psychosocial Support 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By End-user 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018-2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033 7.3.1. Hospitals 7.3.2. Clinics 7.3.3. Ambulatory Surgical Centres 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End-user, 2018-2022 7.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033 8. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018-2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Types 9.2.3. By Treatment 9.2.4. By End-user 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Types 9.3.3. By Treatment 9.3.4. By End-user 9.4. Key Takeaways 10. Latin America Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Types 10.2.3. By Treatment 10.2.4. By End-user 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Types 10.3.3. By Treatment 10.3.4. By End-user 10.4. Key Takeaways 11. Europe Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Types 11.2.3. By Treatment 11.2.4. By End-user 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Types 11.3.3. By Treatment 11.3.4. By End-user 11.4. Key Takeaways 12. South Asia Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Types 12.2.3. By Treatment 12.2.4. By End-user 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Types 12.3.3. By Treatment 12.3.4. By End-user 12.4. Key Takeaways 13. East Asia Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Types 13.2.3. By Treatment 13.2.4. By End-user 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Types 13.3.3. By Treatment 13.3.4. By End-user 13.4. Key Takeaways 14. Oceania Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Types 14.2.3. By Treatment 14.2.4. By End-user 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Types 14.3.3. By Treatment 14.3.4. By End-user 14.4. Key Takeaways 15. MEA Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Types 15.2.3. By Treatment 15.2.4. By End-user 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Types 15.3.3. By Treatment 15.3.4. By End-user 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Types 16.1.2.2. By Treatment 16.1.2.3. By End-user 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Types 16.2.2.2. By Treatment 16.2.2.3. By End-user 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Types 16.3.2.2. By Treatment 16.3.2.3. By End-user 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Types 16.4.2.2. By Treatment 16.4.2.3. By End-user 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Types 16.5.2.2. By Treatment 16.5.2.3. By End-user 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Types 16.6.2.2. By Treatment 16.6.2.3. By End-user 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Types 16.7.2.2. By Treatment 16.7.2.3. By End-user 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Types 16.8.2.2. By Treatment 16.8.2.3. By End-user 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Types 16.9.2.2. By Treatment 16.9.2.3. By End-user 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Types 16.10.2.2. By Treatment 16.10.2.3. By End-user 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Types 16.11.2.2. By Treatment 16.11.2.3. By End-user 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Types 16.12.2.2. By Treatment 16.12.2.3. By End-user 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Types 16.13.2.2. By Treatment 16.13.2.3. By End-user 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Types 16.14.2.2. By Treatment 16.14.2.3. By End-user 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Types 16.15.2.2. By Treatment 16.15.2.3. By End-user 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Types 16.16.2.2. By Treatment 16.16.2.3. By End-user 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Types 16.17.2.2. By Treatment 16.17.2.3. By End-user 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Types 16.18.2.2. By Treatment 16.18.2.3. By End-user 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Types 16.19.2.2. By Treatment 16.19.2.3. By End-user 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Types 16.20.2.2. By Treatment 16.20.2.3. By End-user 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Types 16.21.2.2. By Treatment 16.21.2.3. By End-user 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Types 17.3.3. By Treatment 17.3.4. By End-user 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Merck & Co 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Kyorin Pharmaceuticals 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Pfizer Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Bellus Health 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Eli Lilly and Company 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. GeneScience Pharmaceuticals Co., Ltd. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Johnson & Johnson Private Limited 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Teva Pharmaceutical Industries Ltd. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Sanofi 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Bayer AG 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Edward’s Syndrome Treatment Market
